Drug Trial Radar · NCT06945458
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Apr 17, 2025
Primary completion
Nov 10, 2025
Study completion Nov 10, 2025
Sponsor
- Lead sponsor
- Kymera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
KT-621Drug
Oral drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: From enrollment through the safety follow-up visit on Day 43
- Incidence of treatment-emergent potentially clinically-significant abnormalities in electrocardiogram (ECG) results, vital signs, or laboratory test results from the serum chemistry, hematology (with differential), chemistry, or coagulation panels.Time frame: From enrollment through the safety follow-up visit on Day 43
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Kymera Investigative Site
Birmingham, Alabama
Kymera Investigative Site
Fountain Valley, California
Kymera Investigative Site
Santa Monica, California
Kymera Investigative Site
Boynton Beach, Florida
Kymera Investigative Site
Hollywood, Florida
Kymera Investigative Site
Tampa, Florida
Kymera Investigative Site
Fargo, North Dakota
Kymera Investigative Site
Dublin, Ohio
Kymera Investigative Site
Springfield, Ohio
Kymera Investigative Site
Tulsa, Oklahoma
Kymera Investigative Site
Charleston, South Carolina
Kymera Investigative Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.